ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
update
/
details

Owkin and AstraZeneca Partner to Develop AI-Powered gBRCA Pre-Screening Tool for Breast Cancer

NextEdge Admin

03 Oct 2024

1 min 48 sec

Owkin, an AI-biotech company, has partnered with AstraZeneca to develop an AI-powered tool for pre-screening gBRCA mutations in breast cancer from digitized pathology slides. This collaboration, part of Owkin's ongoing work with Gustave Roussy and The Centre Léon Bérard through the PortrAIt consortium, aims to accelerate access to BRCA testing for more patients. BRCA testing identifies mutations in the BRCA1 and BRCA2 genes, critical for determining cancer risk and guiding treatment, but is often inconsistently offered.

The gBRCA Pre-Screen tool could identify high-risk patients within an hour by analyzing existing pathology material like H&E slides, streamlining the testing process. By expediting BRCA mutation identification, oncologists and genetic counselors can incorporate results into treatment plans more quickly, improving patient outcomes.

Thomas Clozel, MD, CEO of Owkin, emphasized the tool’s potential to reduce care inequity and expand access to tailored treatments. Kristina Rodnikova of AstraZeneca highlighted the collaboration's role in advancing precision medicine by addressing the unmet need for broader BRCA testing. This solution, if widely implemented, could significantly increase BRCA testing in Europe, identifying thousands more gBRCAm patients by 2030.